Axovant dumps nelotanserin in retreat from small molecule R&D

Axovant has halted development of nelotanserin after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The lackluster data persuaded Axovant to drop the drug and complete its pivot from small molecules to gene therapies.